Archive for January, 2017

$EVLV Agrees to Complete #BlockRepurchase from #NBCUniversal

MINNEAPOLIS, Jan. 31, 2017 — Evine Live Inc. (“Evine”) (NASDAQ:EVLV), a multiplatform video commerce company (, today announced that on Monday, January 30, 2017, it agreed to purchase a block of 4,400,000 shares of its common stock, representing approximately 6.9% of shares outstanding, for approximately $4.9 million or $1.12 per share in a private transaction with NBCUniversal Media, LLC, a subsidiary of Comcast Corporation (“Comcast”)(NASDAQ:CMCSA).  The Company will use cash on hand to buy back the shares and the transaction is expected to settle within two business days.

Executive Commentary

Bob Rosenblatt, Chief Executive Officer at Evine, stated, “Comcast and NBCUniversal have and continue to be great business partners, as our network is distributed on Comcast’s cable television systems.  We were happy to work with them to efficiently reduce this non-core investment that Comcast inherited in their acquisition of NBCUniversal in 2011.   We look forward to continuing to partner with Comcast to build a strong future for Evine.”

Other Information

Craig-Hallum Capital Group LLC served as financial advisor to Evine.

No further share repurchases by Evine are contemplated at this time.  The Company does not currently have a share buyback plan in place.

The Company filed a Form 8-K with the SEC today with further details about this transaction.

About Evine Live Inc.
Evine Live Inc. (NASDAQ:EVLV) operates Evine, a digital commerce company that offers a compelling mix of proprietary and name brands directly to consumers in an engaging and informative shopping experience via television, online and on mobile. Evine reaches approximately 87 million cable and satellite television homes 24 hours a day with entertaining content in a comprehensive digital shopping experience.

Please visit for more investor information.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This document contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope, should, plan, will or similar expressions. Any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. These statements are based on management’s current expectations and accordingly are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained herein due to various important factors, including (but not limited to): consumer preferences, spending and debt levels; the general economic and credit environment; interest rates; seasonal variations in consumer purchasing activities; the ability to achieve the most effective product category mixes to maximize sales and margin objectives; competitive pressures on sales; pricing and gross sales margins; the level of cable and satellite distribution for our programming and the associated fees or estimated cost savings from contract renegotiations; our ability to establish and maintain acceptable commercial terms with third-party vendors and other third parties with whom we have contractual relationships, and to successfully manage key vendor relationships and develop key partnerships and proprietary and exclusive brands; our ability to manage our operating expenses successfully and our working capital levels; our ability to remain compliant with our credit facilities covenants; customer acceptance of our branding strategy and our repositioning as a digital commerce company; the market demand for television station sales; changes to our management and information systems infrastructure; challenges to our data and information security; changes in governmental or regulatory requirements; including without limitation, regulations of the Federal Communications Commission, and adverse outcomes from regulatory proceedings; litigation or governmental proceedings affecting our operations; significant public events that are difficult to predict, or other significant television-covering events causing an interruption of television coverage or that directly compete with the viewership of our programming; our ability to obtain and retain key executives and employees; our ability to attract new customers and retain existing customers; changes in shipping costs; our ability to offer new or innovative products and customer acceptance of the same; changes in customers viewing habits of television programming; and the risks identified under “Risk Factors” in our recently filed Form 10-K and any additional risk factors identified in our periodic reports since the date of such Form 10-K. More detailed information about those factors is set forth in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. We are under no obligation (and expressly disclaim any such obligation) to update or alter our forward-looking statements whether as a result of new information, future events or otherwise.


Dawn Zaremba
Evine Live Inc.
(952) 943-6043

Michael Porter
Evine Live Inc.
(952) 943-6517
Tuesday, January 31st, 2017 Uncategorized Comments Off on $EVLV Agrees to Complete #BlockRepurchase from #NBCUniversal

$AKTX to Attend Upcoming Investor Conferences in February

NEW YORK and LONDON, Jan. 31, 2017  — Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will attend and host meetings at two upcoming conferences.

  • Canaccord Genuity 2017 Rare Disease, Biopharma One-on-One Day on Tuesday, February 7, 2017 in New York, NY
  • Leerink Partners 6th Annual Global Healthcare Conference on February 16, 2017 in New York, NY

About Akari Therapeutics Plc

Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of life-transforming treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5 and Leukotriene B4 (LTB4), including paroxysmal nocturnal hemoglobinuria (“PNH”), atypical Hemolytic Uremic Syndrome (“aHUS”), and Guillain Barré syndrome (“GBS”). Akari’s lead product candidate, Coversin™ complement inhibitor, a second-generation complement inhibitor, acts on complement component-C5, preventing the release of C5a and the formation of C5b–9 (also known as the membrane attack complex or MAC), and independently also inhibits LTB4 activity. C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including PNH, aHUS, and GBS. Exploiting the power of nature, Akari is also developing other tick derived proteins and expects to bring additional compounds to clinical trials over the next several years. The pipeline is focused on developing bioengineered versions of native tick salivary proteins that act as anti-inflammatory compounds allowing the tick to remain on its host. These compounds include PGP sparing LTB4 inhibitors, classical and alternative complement inhibitors, anti-histamines, and serotonin inhibitors as examples. Akari is also developing engineered forms that allow for potential oral absorption, as, for example, a potential orally absorbed C5 inhibitor, and tissue specific proteins, as, for example, Coversin™ that acts specifically at the neuromuscular junction for diseases like myasthenia gravis.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: an inability or delay in obtaining required regulatory approvals for Coversin and any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K filed on March 23, 2016. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.



Investor Contact:
The Trout Group
Lee Stern                                    

Media Contact:
Susan Forman / Laura Radocaj
Dian Griesel Int'l.
(212) 825-3210
Tuesday, January 31st, 2017 Uncategorized Comments Off on $AKTX to Attend Upcoming Investor Conferences in February

$MNTA District #Court #Decision Invalidates $TEVA Patents in #COPAXONE

Four of Teva’s Orange-Book listed patents ruled invalid due to obviousness

CAMBRIDGE, Mass., Jan. 31, 2017  — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the United States District Court for the District of Delaware has found each of Teva Pharmaceutical’s U.S. Patent Nos. 8,232,250; 8,399,413; 8,969,302; and 9,155,776  invalid as obvious over the prior art.

“We are very pleased with the District Court’s decision to invalidate the four method of use patents litigated by Teva to block Sandoz’s potential launch of our Glatopa® 40 mg product,” said Craig Wheeler, President and Chief Executive Officer of Momenta. “Today’s favorable ruling further bolsters our confidence in the potential for us to offer multiple sclerosis patients a more affordable generic version of COPAXONE 40 mg following regulatory approval.”

In 2016, the Patent Trial and Appeal Board (PTAB) declared U.S. Patent Nos. 8,232,250, 8,399,413 and 8,969,302 invalid due to obviousness through an Inter Partes Review (IPR) proceeding. Today’s decision confirms that of the PTAB and finds U.S. 9,155,776 invalid on similar grounds. Both the PTAB’s and today’s District Court decision are appealable to the Federal Circuit. In November 2016, Mylan filed a petition asking the PTAB to institute an IPR proceeding against U.S. 9,155,776 patent. A decision on whether that challenge is instituted is due from the PTAB in April 2017.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA.  Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at, which does not form a part of this press release. The company’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements
Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to the approval and launch of our Glatopa product and the invalidity of Teva’s patents, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “could,” “could increase the likelihood,” “hope,” “target,” “project,” “goals,” “potential,” “predict,” “might,” “estimate,” “expect,” “intend,” “is planned,” “may,” “should,” “will,” “will enable,” “would be expected,” “look forward,” “may provide,” “would” or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company’s Quarterly Report on Form 10-Q for the month ended September 30, 2016 filed with the Securities and Exchange Commission under the section “Risk Factors,” as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company’s actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

COPAXONE is a registered trademark of Teva Pharmaceuticals. Glatopa is a registered trademark of Novartis AG.


Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals

Media Relations:
Karen Sharma
MacDougall Biomedical Communications
Tuesday, January 31st, 2017 Uncategorized Comments Off on $MNTA District #Court #Decision Invalidates $TEVA Patents in #COPAXONE

$DRYS Announces Successful Completion of the $200.0 Million #CommonStock Offering

ATHENS, GREECE–(Jan 31, 2017) – DryShips Inc. (NASDAQ: DRYS) (the “Company”), a diversified owner of ocean going cargo vessels, announced today that it has successfully completed the previously announced $200.0 million common stock offering, in which the Company raised net proceeds of $198.0 million, pursuant to the Common Stock Purchase Agreement entered into by the Company on December 23, 2016.

Following the completion of the offering, the Company has approximately 36,253,870 common shares outstanding.

Mr. George Economou, Chairman and CEO, commented:

“We are very excited to have successfully raised $198 million of equity and with total available liquidity in excess of $300 million, we have strengthened our position to continue the process of re-building the Company’s fleet and earnings capacity and pursuing investments in various shipping segments.”

About DryShips Inc.

The Company is a diversified owner of ocean going cargo vessels that operate worldwide. The Company owns a fleet of 13 Panamax drybulk carriers with a combined deadweight tonnage of approximately 1.0 million tons, 1 Very Large Gas Carrier newbuilding and 6 offshore supply vessels, comprising 2 platform supply and 4 oil spill recovery vessels.

The Company’s common stock is listed on the NASDAQ Capital Market where it trades under the symbol “DRYS.”

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with such safe harbor legislation.

Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

Important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the factors related to the strength of world economies and currencies, general market conditions, including changes in charter rates and vessel values, failure of a seller or shipyard to deliver one or more vessels, failure of a buyer to accept delivery of a vessel, our inability to procure acquisition financing, default by one or more charterers of our ships, changes in demand for drybulk or LPG commodities, changes in demand that may affect attitudes of time charterers, scheduled and unscheduled drydocking, changes in our voyage and operating expenses, including bunker prices, dry-docking and insurance costs, changes in governmental rules and regulations, changes in our relationships with the lenders under our debt agreements, potential liability from pending or future litigation, domestic and international political conditions, potential disruption of shipping routes due to accidents, international hostilities and political events or acts by terrorists.

Risks and uncertainties are further described in reports filed by DryShips Inc. with the Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 20-F.

Investor Relations / Media:

Nicolas Bornozis
Capital Link, Inc. (New York)
Tel. 212-661-7566

Tuesday, January 31st, 2017 Uncategorized Comments Off on $DRYS Announces Successful Completion of the $200.0 Million #CommonStock Offering

$NETE #ESET Chooses Net Element’s #PayOnline for Secure #Payments in #Kazakhstan

Leading international IT security company, provider of anti-virus and firewall products chooses PayOnline for secure payments acceptance

MIAMI, FL–(Jan 31, 2017) – Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a provider of global mobile payment technology solutions and value-added transactional services, today announces that ESET, a leading international IT security company which offers anti-virus and firewall products has chosen PayOnline for secure payment acceptance services.

This contract highlights that PayOnline not only serves local companies, but that it is also being selected as platform of choice by international companies looking for a secure platform to accept payments internationally.

ESET develops anti-malware software solutions that protect and secure computers, mobile devices and smartphones. ESET protects Internet users across 200 countries worldwide, making its anti-virus solution one of the leading solutions on the market.

PayOnline provides secure payment acceptance that protects ESET against fraud and consumer’s data in accordance with the highest international payment security standard — PCI DSS (Level 1). Clients of ESET in Kazakhstan can now securely pay online at using multiple payment methods, including MIR, Visa, Visa Electron, MasterCard and Maestro; payments are facilitated in Tenge, Kazakhstan’s national currency.

According to Frost & Sullivan, a leading growth strategies consultancy, “ESET offers high-performance, proactive endpoint security solutions. The company goes above and beyond the competition to add value to its products by educating both Mac and PC users on how to defend themselves against the latest cyber threats… ESET will continue to maintain a strong presence in the endpoint security market and provide high value to its customers.”

“Complex technology can be available, understandable and user-friendly. We believe in it and select partners whose values are similar to ours. Accepting payments at ESET online store utilizing PayOnline fully meets our requirements for quality of service and reliability. We are confident in our payment partner and together we can provide our users with reliable protection,” commented Pavel Brazhnikov, director of Online Projects, ESET.

About ESET
ESET is privately held and has branch offices and distributors in over 200 countries. ESET’s NOD32 anti-virus solution is a record holder for the number of VB100 awards received, according to British publication Virus Bulletin, as well as ADVANCED+ and ADVANCED testing laboratory AV-Comparatives. In Russia, the business version of ESET is FSTEC certified. Further information is available at

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Further information is available at

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to whether the relationship with ESET will positively impact the Company. Additional examples of such risks and uncertainties are : (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element
+1 (786) 923-0502

Tuesday, January 31st, 2017 Uncategorized Comments Off on $NETE #ESET Chooses Net Element’s #PayOnline for Secure #Payments in #Kazakhstan

$MKGI Appoints #RobertPost to #BoardofDirectors

WESTON, FL–(Jan 31, 2017) – Monaker Group, Inc., (OTCQB: MKGI), a technology-driven travel company focused on the alternative lodging rental (ALR) market, has appointed Robert Post, president and CEO of Cloud5 Communications and executive chairman of The Knowland Group, to the company’s board of directors. The appointment increases the board to six members, with four serving independently.

“Bob’s appointment adds a tremendous wealth of senior-level experience, knowledge and accomplishments to our board,” said the company’s chairman and CEO, Bill Kerby. “We expect Bob to provide valuable guidance and insights as the company enters a pivotal period in its growth and development. This includes our near-term launch of the industry’s first-ever ‘real-time’ alternative lodging reservation system, which also offers mainstream travel products and services all on a single site.”

Post is a highly successful entrepreneur, investor, tech-company executive and veteran re-structuring expert with 20 years of success in the travel and hospitality industry. He is currently CEO of Cloud5, the largest provider of cloud based telecommunications and high speed Internet to major brands in the hospitality industry, including Marriott, IHG, Hilton, La Quinta, Motel 6 and Red Roof Inn.

Post was previously chairman and CEO of TravelCLICK, a leading provider of global, hotel e-commerce solutions that supports more than 15,000 customers across 140 countries, including Blackstone, Hilton, Hyatt, Accor, Marriott and Trump. At TravelCLICK, he grew the company from $35 million and breakeven to more than $200 million with high double-digit profitability. Prior to TravelCLICK, he was the CFO and VP of business development of, which was ultimately bought by Priceline for $2.6 billion. He also served as an executive and corporate officer at MICROS Systems, a hospitality technology provider, where he helped lead its secondary NASDAQ offering. Post earlier spent several years at Westinghouse Electric in corporate audit, defense and electronic classified programs, negotiating with the U.S. and foreign governments. He continues to operate Pconsulting, providing start-up investment and restructuring services for mid-sized businesses, including, hotelBANK, and Radiant Systems. He is a graduate of Wharton’s Advanced Management Program, and earned his BS in Business from Duquesne University.

The board appointment is in line with Monaker’s plans for a NASDAQ Stock Market up-listing, which requires a majority of independent directors on the board.

About Monaker

Monaker Group, Inc. is a technology driven travel company with several divisions and brands that build upon more than 65 years of operational experience in leisure travel. Monaker’s flagship NextTrip website is powered by the industry’s first real-time booking engine that offers extensive choices in alternative lodging (vacation home rentals, resort residences and unused timeshares) along with a vast array of airlines, hotels, cruises, rental cars, tours and concierge services, all in a single platform. The site features rich content, imagery and high-quality video that enhances a traveler’s booking experience and assists them in the search, decision and purchasing process. By combining key features and functionality with advanced technology and established travel brands, NextTrip offers comprehensive vacation alternatives at best-pricing. For more information, visit or

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker Group, Inc. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, or the expectations of future growth may not be realized. These forward-looking statements are made only as of the date hereof, and Monaker Group undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker Group’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Company’s Annual Report on Form 10-K for the period ended February 29, 2016 which has been filed with the SEC and is available at the SEC’s website at

Company Contact
Richard Marshall
Director of Corporate Development
Monaker Group
Tel: (954) 888-9779

Investor Relations Contact
Ronald Both or Grant Stude
Tel: (949) 432-7557

Tuesday, January 31st, 2017 Uncategorized Comments Off on $MKGI Appoints #RobertPost to #BoardofDirectors

$AIRI Sells Subsidiary to #MeyerTool

HAUPPAUGE, N.Y., Jan. 30, 2017 — Air Industries Group (NYSE MKT:AIRI) (“Air Industries” or the “Company”), announces on January 27, 2017 that we sold our subsidiary AMK Technical Services to Meyer Tool of Cincinnati Ohio for a purchase price of $ 4,500,000, subject to a customary working capital adjustment, plus additional quarterly payments, not to exceed $ 1,500,000, equal to five percent (5%) of Net Revenues of AMK commencing April 1, 2017.  The purchase price is approximately equal to the purchase price of AMK when acquired in October 2014.

Proceeds of the sale will be used to reduce debt and enhance liquidity.

Separately Air Industries announced that revenue for the year ended December 31, 2016 will be approximately $ 66.8 million dollars, a decline of about $ 14 million dollars from the prior year.

Air Industries Group’s President and CEO, Dan Godin commented, “Earlier this year we announced that we were collaborating with Meyer Tool, co-locating AMK at their site in Poland and eventually in Greenville, South Carolina. As that collaboration developed Meyer Tool expressed an interest in acquiring AMK. While the operations and capabilities of AMK are complementary they are not identical to our core business of producing complex machined aerospace hardware. The divestment of AMK allows Air Industries to focus management and other resources on its core business. Meyer Tool will remain a customer of Air Industries and we hope and expect that our relationship with them will continue to grow in the future.

As we have previously announced, sales results for 2016 were disappointing and a significant decline from the prior year. This decline resulted largely from delays in developing new programs and products, plus a few operational execution issues in our largest sector. During the last half of 2016 we have made significant changes in management at several of our subsidiaries to address this and strengthen our New Product Introduction (NPI) process and Operational Excellence.

Against this disappointment I am pleased to announce that our new business development activities for 2016 were very encouraging with bookings of new business increasing by $ 9 million or 13% to approximately $ 80 million dollars. Our firm 18-month backlog also increased by more than $ 12 million or 16% and is now more than $ 90 million.”


Air Industries Group (NYSE MKT:AIRI) is an integrated manufacturer of precision components and provider of supply chain services for the aerospace and defense industry. The Company has over 50 years of experience in the industry and has developed leading positions in several important markets that have significant barriers to entry. With embedded relationships with many leading aerospace and defense prime contractors, the Company designs and manufactures structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts and flight controls. Air Industries Group also provides sheet metal fabrication, tube bending, and welding services.

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, the ability to realize projected EBITDA, firm backlog and projected backlog, potential future results and acquisitions, are examples of such forward-looking statements. The forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the ability to consummate contemplated acquisitions, the timing of projects due to variability in size, scope and duration, the inherent discrepancy in actual results from estimates, projections and forecasts made by management regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For additional information, please call 631.881.4913 or by email to:
Monday, January 30th, 2017 Uncategorized Comments Off on $AIRI Sells Subsidiary to #MeyerTool

$GNUS Issues Shareholder Letter

BEVERLY HILLS, CA–(January 30, 2017) – Genius Brands International (NASDAQ: GNUS) recently released a letter to shareholders from Chairman & CEO Andy Heyward. The complete letter follows:

Dear Shareholders,

Some people have asked me in the last week, what’s going on with our stock price. In the past two months, it’s been as high as $8.00 dollars and as low as $3.85. Of course, I don’t like to see this kind of fluctuation, and neither the highs nor the lows accurately reflect the business.

As your CEO, I can’t control stock prices going up and down. I can, however, focus on growing our business and building assets, which ultimately is creating the value in the company. Eventually, we know stock prices align with value.

That is EXACTLY what we have been doing at Genius Brands, and the result is that over the last three years, we have created a powerful catalogue of kid’s content (encompassing seven different brands and an equally powerful distribution outlet, Kid Genius Cartoon Channel). Both are highly valuable and desirable items, which quite often get sold to bigger companies in the food chain (major studios, networks, phone companies, cable companies, etc.).

Here are some facts to remember:

We have more positive events occurring in Genius Brands today than at any time before. I would add, even more than when I sold my previous company to Disney and to Cookie Jar for many multiples of what we trade at.

  • More brands, both in and coming to the marketplace
  • More licensees
  • More committed retailers
  • More catalogue in use
  • A rapidly growing kids channel currently in 50 million U.S. television households, and we are in negotiations, which will put it at over 75+ million U.S. television households by the end of this quarter. (Note, there are a total of 105 million U.S. television households. At 75 million, Kid Genius Cartoon Channel will be able to reach three out of four kids in the U.S.)

The creation of children’s characters, and licensing consumer products around them, is the same business,

1. that drove the sale of DreamWorks for $3.4 billion dollars to Universal.

2. that drove the sale of Marvel for $4+ billion dollars to Disney.

The creation of our Kid Genius Cartoon Channel distribution system, which can deliver kids content to greater than 60% of U.S. television households,

1. is the same business that drove the sale of FOX Kids to Disney for $5.4 billion.

2. is the same business that drove the sale of the HUB to Hasbro and eventually Discovery.

We have powerful and committed partners that are engaged in our brands and businesses, including:

  • Netflix
  • General Mills
  • YouTube
  • Comcast
  • Sony Music/Sony Pictures Home Entertainment
  • Target
  • Toys”R”Us
  • Amazon
  • Penguin Books


These partnerships and others including broadcasters, publishers , toy companies, electronics, and key licensees, provide an ‘architecture and ecosystem’ for bringing our properties to the consumer, and to make money…just as I have done with our key management many times before. These companies are smart, wired, and selective. They don’t enter relationships with unproven parties nor with properties that they don’t believe can become extremely successful, and they usually do.

The relationship with Sony Pictures Home Entertainment is PARTICULARLY meaningful. Not only are they a strategic business partner on multiple businesses, but they recently took a 7% investment in the company. They have a firm commitment to grow their own kid’s business through their relationship with Genius Brands.

When I had the good fortune to ring the NASDAQ closing bell last week, Sony had a Senior Vice President there WITH ME on the platform. In 2017 and beyond, they will be releasing more and more of our properties into the marketplace as our global digital content distributor.

I have said it takes three years to create, produce, distribute, and bring our content ultimately to the retail shelf. We now have the first of our properties, SpacePOP, on shelf in a big way. We have the licensees; we have the retail support; and we have the content, which has millions and millions of views and continues to grow every day.

What is required is PATIENCE.

In October, our second property will debut, Llama Llama, for Netflix and stars Jennifer Garner. We are well along in production, and our delivery to Netflix in October will not only trigger the beginning of several million dollars of payments from them, but also an array of advances and guarantees from merchandise, which will then be on retail shelves everywhere.

Warren Buffett, has said over and over again that patience is the most important discipline required of an investor. He even put it inside the curriculum of our Secret Millionaires Club. Few have it, but those who do, win.

We have powerful value drivers occurring in Genius Brands, and I encourage you to watch now as they come to market.

Andy Heyward
Chairman & CEO
Genius Brands International


Investor Relations
Porter, LeVay and Rose
Michael Porter
T: 212-564-4700
Email contact

Monday, January 30th, 2017 Uncategorized Comments Off on $GNUS Issues Shareholder Letter

$RTTR Rings @NASDAQ #ClosingBell #LactoseIntolerance Awareness Month

LOS ANGELES, CA–(Marketwired – Jan 30, 2017) – Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, will be ringing the closing bell for the Nasdaq stock market in New York today, Monday, January 30, 2017 at 4:00 p.m. EST to kick-off Lactose Intolerance Awareness Month.

Ira E. Ritter, Co-founder and Chairman of Ritter Pharmaceuticals’ Board of Directors, commented, “Its important to make people aware that lactose intolerance dramatically affects over 40 million people in the U.S. of which 9 million suffer moderate to severe symptoms. Lactose Intolerance is a condition with few treatment options where over 50% of sufferers report their intolerance moderately or severely impacts their daily activities.1 There is a huge unmet medical need here and we have dedicated our last 13 years to pursuing the development of a better treatment option.”

Ritter Pharmaceuticals’ lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance. RP-G28 was recently studied in a 377-subject Phase 2b/3 clinical trial, with data readout expected this quarter.

“The Company has had a busy start to 2017,” said Michael Step, Chief Executive Officer of Ritter Pharmaceuticals “We announced the publication of our Phase 2a study’s microbiome data in the prestigious peer-reviewed journal Proceedings of the National Academy of Sciences, established a collaboration with the University of Nebraska to study the role of the microbiome and RP-G28 in metabolic syndrome, and appointed William Merino, Ph.D., a former Senior Vice President of Worldwide Regulatory Affairs at Warner Lambert Pharmaceuticals, to our Board of Directors.”

Chairman, Co-Founder and Chief Strategic Officer Ira E. Ritter ringing the Nasdaq bell can be viewed live today, Monday, January 30, 2017 at 4:00 p.m. EST via a live webcast:

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. The company is further exploring functionality and discovering therapeutic potential gut microbiome changes may have on treating/preventing a variety of areas including: gastrointestinal diseases, immune-oncology, metabolic, and liver disease. For additional information, go to and follow the Company at @RitterPharma.

Forward-Looking Statements

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the release of results from the Company’s Phase 2b/3 clinical trial of RP-G28. Management believes that these forward-looking statements are reasonable as and when made. However, such statements involve a number of known and unknown risks and uncertainties that could cause the Company’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process. For a discussion of certain risks and uncertainties affecting Ritter Pharmaceuticals’ forward-looking statements, please review the Company’s reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2015 and Quarterly Reports on Form 10-Q for the periods ended March 31, 2016, June 30, 2016 and September 30, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management’s current expectations and Ritter Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law.

1 Objective Insights, “Market Research Analysis and Forecasts on Lactose Intolerance and RP-G28.” June, 2012.

Ellen Mochizuki

Monday, January 30th, 2017 Uncategorized Comments Off on $RTTR Rings @NASDAQ #ClosingBell #LactoseIntolerance Awareness Month

$DGLY Huge 6,500 Unit Order #DVM250 In-Car #EventRecorderSystems

LENEXA, KS–(Jan 30, 2017) – Digital Ally, Inc. (NASDAQ: DGLY) (“Digital or the “Company”), which develops, manufactures and markets advanced video surveillance products for law enforcement, homeland security and commercial applications, today announced its largest commercial order ever received for the sale and installation of DVM-250 event recorder video systems to American Medical Response (“AMR”) and ongoing FleetVu Manager cloud storage services. AMR’s initial order for deployment during 2017 includes approximately 1,550 three-camera DVM-250 systems, installation and cloud storage services, representing 2017 revenues approximating $2 million. Shipments will begin immediately.

AMR is one of the largest providers of emergency medical transportation and other industry services in the United States. The initial order involves fleet vehicles for emergency medical transportation. AMR plans to deploy DVM-250 event recorders and in its full fleet of 6,500-plus vehicles during 2018 and 2019, which would increase the potential total contract value to over $8.3 million during the three-year deployment period.

“We are pleased to see continued growth in Digital Ally’s commercial fleet solutions at the start of 2017 and are proud to be selected by AMR for this important full-fleet deployment,” said Stan Ross, Chief Executive Officer of Digital Ally, Inc. “We have begun to see the Company’s service revenue strategy come to fruition as we secure commercial contracts for the DVM-250 systems, as well as for our FleetVu Manager cloud services that provide a recurring revenue stream,” explained Ross. “This order demonstrates the importance of our solution to commercial fleets generally and more specifically to emergency medical/ambulance transportation services. Our system provides fleet managers audio/video equipment to easily monitor driver behavior and mitigate liabilities during patient transportation,” Ross continued. “In addition to our standard top of the line DVM-250 event recorder systems, AMR will use sensor monitoring to generate a recording when the vehicle’s back doors open and close. In some instances, AMR also took advantage of various innovative product upgrades, such as a fourth camera angle, audible driver feedback and asset tracking. Our product’s versatility and the ability to offer features such as these are among the reasons more vehicle fleets are choosing Digital Ally as their audio/video provider,” Ross concluded.

FleetVu Manager adds powerful real-time asset tracking, automated alerts and telematics capabilities for our customers. Software options include live asset tracking and mapping, posted speed violations and customizable real-time alerts such as idle time, collisions, geo fences and speeding. FleetVu Cloud enables agency managers to easily monitor their fleet of vehicles and driver performance. Users can store and manage video, update firmware and wireless configurations while using features such as mapping, reporting and creating driver score cards. FleetVu mobile allows drivers to perform pre- and post-inspections of the vehicle. It instantly sends alerts via SMS or email to fleet managers if there is a breakdown, maintenance request or any issue with that vehicle. As a result, the system may be instrumental in reducing accidents, fraud and litigation risks.

About Digital Ally, Inc.

Digital Ally, Inc. develops, manufactures and markets advanced technology products for law enforcement, homeland security and commercial applications. The Company’s primary focus is digital video imaging and storage. The Company is headquartered in Lenexa, Kansas, and its shares are traded on The Nasdaq Capital Market under the symbol “DGLY.” For additional news and information please visit or follow us on Twitter @digitalallyinc and Facebook

Follow additional Digital Ally Inc. social media channels here:
LinkedIn Instagram Google+ Pinterest

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: whether AMR will fully implement its three-year plan to equip its vehicles with the Company’s DVM-250 products and utilize related services; whether a growing number of commercial customers will choose the Company as their provider; competition from larger, more established companies with far greater economic and human resources; the effect of changing economic conditions; and changes in government regulations and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company’s disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “projects”, “should”, or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in its annual report on Form 10-K for the year ended December 31, 2015 and quarterly report on Form 10-Q for the three and nine months ended September 30, 2016, as filed with the Securities and Exchange Commission.

For Additional Information, Please Contact:
Stanton E. Ross
(913) 814-7774
Thomas J. Heckman
(913) 814-7774

Monday, January 30th, 2017 Uncategorized Comments Off on $DGLY Huge 6,500 Unit Order #DVM250 In-Car #EventRecorderSystems

$CALA & $INCY Announce #Global #CB1158 #Collaboration Arginase Inhibitor

  • Incyte gains worldwide rights to CB-1158 for hematology and oncology indications
  • Calithera to receive a $45 million up-front payment and an $8 million equity investment
  • Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158
  • Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT

Incyte Corporation (NASDAQ:INCY) and Calithera Biosciences, Inc. (NASDAQ:CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology. CB-1158 is currently being studied in a monotherapy dose escalation trial and additional studies are expected to evaluate CB-1158 in combination with immuno-oncology agents, including anti-PD-1 therapy.

This Smart News Release features multimedia. View the full release here:

“Arginase-expressing tumor-infiltrating myeloid cells have been shown to play an important role in orchestrating the immune suppressive microenvironment in cancer; but, to date, therapeutic targeting of the arginase enzyme has remained elusive,” said Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “The addition of this first-in-class, small molecule arginase inhibitor, CB-1158, to our portfolio expands our innovative immuno-oncology pipeline and allows us to continue to advance our mission of discovering and developing immune-active combination therapies to treat patients with cancer.”

“In this strategic partnership with Incyte, CB-1158 is expected to be evaluated in multiple trials of novel therapeutic combinations, accelerating its development across hematological and oncology indications,” said Susan Molineaux, Ph.D., Calithera’s Chief Executive Officer.

Terms of the Collaboration

Under the terms of the collaboration and license agreement, Calithera will receive an up-front payment of $45 million from Incyte. In addition, Incyte will make an equity investment in Calithera of $8 million through the purchase of shares at a price of $4.65 per share.

Incyte will receive worldwide rights to develop and commercialize CB-1158 in hematology and oncology and Calithera will retain certain rights to research, develop and commercialize certain other arginase inhibitors in certain orphan indications.

Incyte and Calithera will jointly conduct and co-fund development of CB-1158, with Incyte leading global development activities. Incyte will fund 70 percent of global development and Calithera will be responsible for the remaining 30 percent. In the event of regulatory approvals and commercialization of CB-1158, Incyte and Calithera will share in any future U.S. profits and losses (receiving 60 percent and 40 percent, respectively) and Calithera will be eligible to receive over $430 million in potential development, regulatory and commercialization milestones from Incyte. Per the terms of the agreement, Calithera will have the right to co-detail CB-1158 in the U.S. and also be eligible to receive from Incyte tiered royalties based on future ex-U.S. sales, with rates ranging from low-to-mid double-digits.

The agreement also provides that Calithera may choose to opt out of its co-funding obligations. In this scenario, Calithera would no longer be eligible to receive future U.S. profits and losses but would be eligible to receive up to $750 million in potential development, regulatory and commercialization milestones from Incyte and, if the product is approved and commercialized, also be eligible to receive reimbursement based on previous development expenditures incurred by Calithera and tiered royalty payments on future global sales of CB-1158, with rates ranging from low-to-mid double-digits.

The transaction is expected to close in the first quarter of 2017, subject to customary closing conditions.

Conference Call and Webcast Information

Calithera will host a conference call today to discuss this collaboration at 8:30 a.m. ET, 5:30 a.m. PT. Participants may access the call by dialing (855)783-2599 (domestic) or (631)485-4877 (international) and referencing conference ID 58716954. The conference call will also be available by webcast in the Investor Relations page of Calithera’s website, The archived webcast will remain available for replay for 30 days.

About Arginase

Arginase is an enzyme produced by immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and neutrophils, which prevents T-cell and natural killer (NK) cell activation in tumors. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the tumor microenvironment which subsequently prevents activation and proliferation of the immune system’s cytotoxic T-cells and NK-cells. Inhibition of arginase activity reverses this immunosuppressive block and restores T-cell function. In preclinical models, arginase inhibition has been shown to enhance anti-tumor immunity and inhibit tumor growth.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at

Follow @Incyte on Twitter at

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is currently in a Phase I clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether CB-1158 will successfully advance through clinical studies or will ever be approved for use in humans anywhere or will be commercialized anywhere successfully or at all; whether CB-1158 will be effective in the treatment of cancer; and whether and when any of the milestone payments or royalties under this collaboration will ever be paid by Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining approval for this planned collaboration; research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors; unanticipated delays; each company’s ability to compete against parties with greater financial or other resources; greater than expected expenses; and such other risks detailed from time to time in each company’s reports filed with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2016 filed by each company. Each party disclaims any intent or obligation to update these forward-looking statements.


Incyte Media
Catalina Loveman, 302-498-6171
Incyte Investors
Michael Booth, DPhil, 302-498-5914
Jennifer McNealey, 650-870-1071

Monday, January 30th, 2017 Uncategorized Comments Off on $CALA & $INCY Announce #Global #CB1158 #Collaboration Arginase Inhibitor

$CIIX to Present at #NobleCon13 Annual #Investor #Conference

NEW YORK, January 30, 2017  — (OTCQB: CIIX) (the “Company”), the premier financial information website for Chinese-speaking investors in both the U.S. and China today announced that its CEO, Warren Wang, will present at the NobleCon13 – Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on January 31st at 2:30pm Eastern Standard Time.

A high-definition, video webcast of the company’s presentation and a copy of the presentation materials will be available on the Company’s web site, or as part of a complete catalog of presentations available at Noble Financial websites:, or You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company’s website and on the Noble websites for 90 days following the event.


Founded in 1999,, Inc. endeavors to be an innovative company providing (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) support services to various partners; (c) consultative services to smaller private companies considering becoming a public company; (d) advertising and public relation related support services; and (e) other services we may identify having the potential to create value or partnership opportunity with our existing services.

About Noble Capital Markets, Inc.

Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York and Boston. In addition to NobleCon – the annual multi-sector investor conference and the Media, Finance & Investor Conference, produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas, throughout the year Noble hosts numerous “non-deal” corporate road shows across the United States and Canada. Members: FINRA, SIPC, MSRB.


Alan Klitenic


Monday, January 30th, 2017 Uncategorized Comments Off on $CIIX to Present at #NobleCon13 Annual #Investor #Conference

$FBIZ Announces an #Increase in its #Quarterly #Dividend

MADISON, Wis., Jan. 27, 2017  — First Business Financial Services, Inc. (“First Business”) (NASDAQ:FBIZ) announced its board of directors has declared a quarterly cash dividend on its common stock of $0.13 per share which is equivalent to a dividend yield of 2.13% based on Thursday’s market close price of $24.36. The quarterly dividend at this amount represents an 8.3% increase over the quarterly dividend declared in October 2016.  On an annualized basis, the 2017 dividend amount is $0.52 per share, or a payout ratio of 28% based on fourth quarter 2016 earnings. This regular cash dividend is payable on February 24, 2017 to shareholders of record at the close of business on February 10, 2017.

Corey Chambas, President and Chief Executive Officer commented, “We are pleased to announce an increase in our quarterly dividend to $0.13 reflecting our commitment to increasing shareholder value. We believe our earnings and capital position give us the ability to increase dividends and provide a meaningful return to our shareholders while carrying out our strategic growth initiatives.”

About First Business Financial Services, Inc.
First Business Financial Services is a Wisconsin-based bank holding company, focused on the unique needs of businesses, business executives and high net worth individuals. First Business offers commercial banking, specialty finance and private wealth management solutions, and because of its niche focus, is able to provide its clients with unmatched expertise, accessibility and responsiveness. For additional information, visit or call 608-238-8008.

This press release includes “forward-looking” statements related to First Business Financial Services, Inc. that can generally be identified as describing the Company’s future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company’s future results, please see the Company’s 2015 annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission.


Edward G. Sloane, Jr.
Chief Financial Officer
First Business Financial Services, Inc.
Friday, January 27th, 2017 Uncategorized Comments Off on $FBIZ Announces an #Increase in its #Quarterly #Dividend

$ARLP & $AHGP Declare #Q4 Unitholder Distribution

Alliance Resource Partners, L.P. (NASDAQ: ARLP) and Alliance Holdings GP, L.P. (NASDAQ: AHGP) today announced that the Board of Directors of ARLP’s managing general partner and AHGP’s general partner approved a cash distribution to their respective unitholders for the quarter ended December 31, 2016 (the “2016 Quarter”).

ARLP unitholders will receive a cash distribution for the 2016 Quarter of $0.4375 per unit (an annualized rate of $1.75 per unit), payable on February 14, 2017 to all unitholders of record as of the close of trading on February 7, 2017. The announced distribution is equal to the distribution declared for the quarter ended September 30, 2016 (the “Sequential Quarter”) and compares to the quarterly unitholder distribution of $0.675 per unit for the quarter ended December 31, 2015 (the “2015 Quarter”).

AHGP unitholders will receive a cash distribution for the 2016 Quarter of $0.55 per unit (an annualized rate of $2.20 per unit), payable on February 17, 2017 to all unitholders of record as of the close of trading on February 10, 2017. The announced distribution is equal to the distribution declared for the Sequential Quarter and compares to the quarterly unitholder distribution of $0.96 per unit for the 2015 Quarter.

As previously announced, ARLP and AHGP will report financial results for the 2016 Quarter and full year before the market opens on Monday, January 30, 2017 and Alliance management will discuss these results during a conference call beginning at 10:00 a.m. Eastern that same day.

To participate in the conference call, dial (855) 793-3259 and provide conference number 48863667. International callers should dial (631) 485-4928 and provide the same conference number. Investors may also listen to the call via the “investor information” section of ARLP’s website at or AHGP’s website at

An audio replay of the conference call will be available for approximately one week. To access the audio replay, dial (855) 859-2056 and provide conference number 48863667. International callers should dial (404) 537-3406 and provide the same conference number.

This announcement is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b), with 100% of the partnership’s distributions to foreign investors attributable to gross income, gain or loss that is effectively connected with a United States trade or business. Accordingly, ARLP’s distributions to foreign investors are subject to federal income tax withholding at the highest applicable tax rate.

About Alliance Resource Partners, L.P.

ARLP is a diversified producer and marketer of coal to major United States utilities and industrial users. ARLP, the nation’s first publicly traded master limited partnership involved in the production and marketing of coal, is currently the second largest coal producer in the eastern United States with mining operations in the Illinois Basin and Appalachian coal producing regions.

ARLP currently operates eight mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana.

News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission, are available at For more information, contact the investor relations department of Alliance Resource Partners, L.P. at (918) 295-7674 or via e-mail at

About Alliance Holdings GP, L.P.

AHGP is a limited partnership formed to own and control Alliance Resource Management GP, LLC, the managing general partner of Alliance Resource Partners, L.P. (NASDAQ: ARLP), through which it holds a 1.98% general partner interest and the incentive distribution rights in ARLP. In addition, AHGP owns 31,088,338 common units of ARLP.

News, unit prices and additional information about AHGP including filings with the Securities and Exchange Commission, are available at For more information, contact the investor relations department of Alliance Holdings GP, L.P. at (918) 295-1415 or via e-mail at


Alliance Holdings GP, L.P.
Alliance Resource Partners, L.P.
Brian L. Cantrell, 918-295-7673

Friday, January 27th, 2017 Uncategorized Comments Off on $ARLP & $AHGP Declare #Q4 Unitholder Distribution

$AUPH Worldwide #ClinicalTrials as its #CRO for #Phase3 #Lupus Nephritis Trial

– Single Phase 3 Trial on track to commence in Q2 2017

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has selected Worldwide Clinical Trials (“Worldwide”) as its Clinical Research Organization (CRO) for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis (LN).

“Selecting a CRO for AURORA is a key milestone for Aurinia following our successful end-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) Division of Pulmonary, Allergy and Rheumatology Products. We are thrilled to partner with Worldwide to support the AURORA Phase 3 clinical trial,” said Charles Rowland, Chief Executive Officer of Aurinia. “We are rapidly moving forward with our plans to bring this important therapy to market for patients living with this devastating disease, and Worldwide’s deep expertise and capabilities in managing pivotal trials will be a tremendous asset to us. We are on track to commence the AURORA trial in the second quarter of 2017, and we expect the results from this study will support a New Drug Application (NDA) submission to the FDA.”

With support from Worldwide, Aurinia will proceed with conducting a randomized, placebo-controlled, double-blind global 52-week trial in approximately 320 patients. The primary endpoint as in the Phase 2b AURA trial is renal response (complete remission), at 24 weeks. In addition to the assessment of renal response, a key marker of clinical benefit in this population is the duration of proteinuria improvement. Therefore, secondary endpoints will include the duration of renal response at 52 weeks (48 weeks in AURA), an efficacy measure which delineates durability of renal response (remission), an important parameter in evaluating long-term outcomes for the treatment of LN.

“Our entire Worldwide team is delighted to have been selected as Aurinia’s CRO partner to advance voclosporin, which has the potential to become the first FDA-approved treatment for LN,” said Peter Benton, President and Chief Operating Officer at Worldwide Clinical Trials. “We’re truly honored that an innovator like Aurinia recognizes what Worldwide brings to the table: medical and scientific expertise, proactive insight, dogged determination, rigorous processes and a commitment to getting it right. We’re looking forward to working closely with Aurinia’s clinical development team on this new therapy, which could significantly improve the lives and long-term outcomes of patients suffering from LN.”

About Voclosporin

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in LN when added to standard of care (MMF). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses. It is made by a modification of a single amino acid of the cyclosporine molecule which has shown a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency, an altered metabolic profile, and potential for flat dosing. The Company anticipates that upon regulatory approval, patent protection for voclosporin will be extended in the United States and certain other major markets, including Europe and Japan, until at least October 2027 under the Hatch-Waxman Act and comparable laws in other countries.

About Lupus Nephritis (LN)

Lupus Nephritis (LN) in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious progression of SLE. SLE is a chronic, complex and often disabling disorder and affects more than 500,000 people in the United States (mostly women). The disease is highly heterogeneous, affecting a wide range of organs & tissue systems. It is estimated that as many as 60% of all SLE patients have clinical LN requiring treatment. Unlike SLE, LN has straightforward disease outcomes where an early response correlates with long-term outcomes, measured by proteinuria. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR), and increased serum creatinine levels. LN is debilitating and costly and if poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially life-threatening condition.


The AURORA study is a 52-week global double-blind placebo controlled Phase III study that will compare the efficacy of one dose of voclosporin (23.7mg BID) or placebo added to current standard of care of mycophenolate mofetil (MMF, also known as CellCept®) in achieving renal response (formerly referred to as complete remission) in patients with active LN. Both arms will also receive low doses of corticosteroids as part of background therapy after a stringent taper. Aurinia believes this Phase III clinical trial whose design is consistent with the ongoing AURA study, will support a New Drug Application (NDA) submission.

About Aurinia

Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN). The company is headquartered in Victoria, BC and focuses its development efforts globally.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit


Forward Looking Statements

This press release contains forward-looking statements, including statements related to Aurinia’s clinical and regulatory strategy, future clinical development plans, Aurinia’s analysis, assessment and conclusions of the results of the AURA-LV clinical study. It is possible that such results or conclusions may change based on further analyses of these data. Words such as “plans,” “intends,” “may,” “will,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Aurinia’s current expectations. Forward-looking statements involve risks and uncertainties. Aurinia’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Aurinia’s analyses, assessment and conclusions of the results of the AURA-LV clinical study set forth in this release may change based on further analyses of such data, and the risk that Aurinia’s clinical studies for voclosporin may not lead to regulatory approval. These and other risk factors are discussed under “Risk Factors” and elsewhere in Aurinia’s Annual Information Form for the year ended December 31, 2015 filed with Canadian securities authorities and available at and on Form 40-F with the U.S. Securities Exchange Commission and available at, each as updated by subsequent filings, including filings on Form 6-K. Aurinia expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aurinia’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


Aurinia Pharmaceuticals Inc.
Investor & Media Contact:
Celia Economides
Head of IR & Communications
Worldwide Clinical Trials Media Contact:
LuJean Smith, +1.610.329.2056
Vice President, Global Marketing Communications

Friday, January 27th, 2017 Uncategorized Comments Off on $AUPH Worldwide #ClinicalTrials as its #CRO for #Phase3 #Lupus Nephritis Trial

$HBMD Prices #Upsized #PublicOffering of #CommonStock

Howard Bancorp, Inc. (Nasdaq:HBMD) (the “Company”), the parent company of Howard Bank, today announced the pricing of an upsized underwritten public offering of 2,400,000 shares of its common stock at a public offering price of $15.00 per share, raising approximately $36.0 million in gross proceeds. The Company has granted the underwriters a 30-day option to purchase up to an additional 360,000 shares of its common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any.

The Company intends to use the net proceeds from the offering for general corporate purposes, including contributing to the capital of Howard Bank to support its lending and investing activities, repayment of debt and to support or fund acquisitions of other institutions or branches as and if opportunities for such transactions become available.

Raymond James & Associates, Inc. is serving as bookrunning manager and Stephens Inc. is serving as lead manager. The closing of the transaction is subject to customary closing conditions. The shares are expected to be delivered on February 1, 2017.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. The offering will be made only by means of a prospectus and prospectus supplement. Copies of the prospectus and, when available, prospectus supplement for the offering may be obtained by visiting the SEC website at or by contacting: Raymond James & Associates, Inc., 880 Carillon Parkway, St. Petersburg, Florida 33716, (800)-248-8863 or by email at

About Howard Bancorp, Inc.

Howard Bancorp, Inc. is the parent company of Howard Bank, is a Maryland-chartered trust company operating as a commercial bank. Headquartered in Ellicott City, Maryland, Howard Bank operates a general commercial banking business through its 13 branches located throughout the Greater Baltimore Metropolitan Area. It had consolidated assets of approximately $1.0 billion at December 31, 2016. Additional information about Howard Bancorp, Inc. and Howard Bank are available on its Web site at


Howard Bancorp, Inc.
George C. Coffman, 410-750-0020
Chief Financial Officer

Friday, January 27th, 2017 Uncategorized Comments Off on $HBMD Prices #Upsized #PublicOffering of #CommonStock

$PULM $CARA #Biotech #MergersAndAcquisitions Activity to Rise in 2017

NEW YORK, NY / January 27, 2017 / The Biotech Industry witnessed a drop in mergers and acquisitions (M&A) activity amidst a slump in 2016. The Nasdaq Biotech Index declined roughly 22 percent in 2016. M&A activity within the Biotech Industry totaled 326 deals worth approximately $91 billion in 2016, compared to $118 billion the year prior, according to Bloomberg. Also the number of M&A deals in the sector in 2016 was the lowest total in six years. Research & development productivity of 12 of the biggest biopharma companies, which was measured by annual projected R&D returns, hit a 7 year low in 2016, according to a recent study completed by Deloitte. With many large firms having more cash available, giving them plenty of firepower for larger number of in M & A activities in 2017.

Register with us now for your free membership and gain access to our latest research reports at:

“With a large gap remaining between large BioPharma’s actual and desired revenues, and historically high amounts of cash on hand, look for an uptick of larger acquisition targets,” says David Risinger, an analyst for Morgan Stanley who covers big pharma. “This is particularly true of the U.S. BioPharma industry, where the amount of cash on hand is greater and intentions more focused.”

Pulmatrix Inc. (NASDAQ: PULM)

Get Your Up-To-Date Pulmatrix Research Report Click Here

Pulmatrix’s shares surged 35.37 percent to close at $2.22 a share Thursday. The stock traded between $1.42 and $2.59 on volume of 20.32 million shares traded. On January 17th, the company announced PUR1900, a drug candidate for the treatment of fungal infections in the lungs of CF patients, received the “Qualified Infectious Disease Product” (QIDP) designation from the U.S. Food & Drug Administration.

“The new QIDP designation is a significant boost to our efforts to make this drug available as quickly as possible to cystic fibrosis (CF) patients suffering from fungal lung infections,” said Pulmatrix CEO Robert Clarke, PhD. “It will give us the benefit of an expedited regulatory review. Added to our existing FDA Orphan drug designation for PUR1900, it will give us a full 12 years of market exclusivity.”

Cara Therapeutics Inc. (NASDAQ: CARA)

Get Your Up-To-Date Cara Therapeutics Research Report Click Here

Cara Therapeutics’ shares jumped 6.26 percent to close at $13.74 a share Thursday. The stock traded between $12.93 and $13.98 on volume of 2.29 million shares traded. Cara’s most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritus. This compound possesses analgesic, anti-inflammatory and anti-pruritic activities appropriate for multiple therapeutic applications. On November 29th, the company announced the completion of patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in dialysis patients suffering from moderate-to-severe uremic pruritus (UP).

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of and reviewed by Hemal K. Gandhi, a CFA® charter holder. is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Friday, January 27th, 2017 Uncategorized Comments Off on $PULM $CARA #Biotech #MergersAndAcquisitions Activity to Rise in 2017

$WASH #CommercialFinancing Development of Property in #Dedham, #MA

WESTERLY, R.I., Jan. 26, 2017  — Washington Trust’s Commercial Real Estate Group recently provided commercial financing to Dedham Retail Realty Ventures for the development of a two-parcel property directly across from Legacy Place, a 600,000 square-foot open air shopping, dining and entertainment destination in Dedham, MA.

The new property includes two retail buildings, totaling approximately 11,500 square feet of space. Tenants include Sprint, Select Comfort, Starbucks and Red Wing shoes. Demand for the properties is strong due to its great visibility and location on a highly trafficked retail corridor.

“This property has a superb location that was instrumental in its leasing momentum,” said Julia Anne M. Slom, Senior Vice President & Team Leader of Washington Trust’s Commercial Real Estate Group. “The plaza serves as a great compliment to surrounding retail development.”

Washington Trust’s Commercial Real Estate Group provides commercial real estate mortgages for the construction, refinancing, or purchasing of investment real estate projects. Financing ranges in size from several hundred thousand dollars up to multi-million dollar projects. For more information, contact Bethany Lyons, Vice President, Commercial Real Estate Group, at 401-401-1538 or 1-800-475-2265 ext. 1538.

Founded in 1800, Washington Trust is the oldest community bank in the nation and one of the Northeast’s premier financial services companies. Washington Trust offers a full range of financial services, including commercial banking, mortgage banking, personal banking and wealth management and trust services through its offices located in Rhode Island, Connecticut and Massachusetts. The Washington Trust Company is a subsidiary of Washington Trust Bancorp, Inc., (NASDAQ:WASH). Additional information on Washington Trust and its subsidiaries can be found at

Tony Nunes
Public Relations 
Thursday, January 26th, 2017 Uncategorized Comments Off on $WASH #CommercialFinancing Development of Property in #Dedham, #MA

$GWGH #BrianChen to Lead Development of #Epigenetic #MortalityPrediction Technology

MINNEAPOLIS, Jan. 26, 2017  — GWG Holdings, Inc. (Nasdaq:GWGH), a financial services company applying epigenetic technology to transform the life insurance industry, announced it has hired Dr. Brian Chen to lead its new initiative to measure and predict human lifespan.

As Vice President of Research and Analytics, Dr. Chen will be responsible for developing and implementing GWG’s new life insurance underwriting process using “DNA Methylation-Based Predictor of Mortality” technology optioned from the University of California, Los Angeles (UCLA). The technology developed by Dr. Steve Horvath at UCLA will be used by GWG to more accurately assess the life expectancies of policy owners. GWG is in the process of integrating this technology into its actuarial underwriting method to enhance its current secondary market business, as well as explore even greater opportunities in the life insurance industry.

“Brian will play a key role in bringing to market our proprietary approach that uses epigenetic technology to determine estimates of an individual’s lifespan,” said GWG CEO Jon Sabes. “His experience working with Dr. Steve Horvath and the technology we have optioned from UCLA will accelerate our development of new procedures and products. Our goal is to rewrite the century-old ways of life insurance underwriting and reinvent the industry in doing so. This is an exciting opportunity for us as we push forward into the insurtech space where insurance and technology meet.”

Dr. Chen worked closely with Dr. Horvath at UCLA as an epidemiologist who studied the biological underpinnings of aging and age-related diseases. Dr. Chen was first author of the study on DNA methylation and mortality prediction building on Dr. Horvath’s work that was published in the journal Aging in September 2016.  Most recently, Dr. Chen worked at the National Institute on Aging (NIA) as a postdoctoral researcher. Prior to coming to the NIA, Dr. Chen worked at the National Heart, Lung, and Blood Institute’s Framingham Heart Study that provided important blood samples for the UCLA team’s work. Dr. Chen received his Ph.D. in epidemiology from UCLA and Master’s in Public Health from the University of California at Berkeley.

About GWG Holdings, Inc.

GWG Holdings, Inc. (Nasdaq:GWGH) is a financial services company committed to applying advanced epigenetic mortality prediction technology to the life insurance and related industries. Already a recognized disruptor in the life insurance secondary market, GWG seeks to further transform the industry by continuing to create innovative products and services. As of September 30, 2016, GWG’s growing portfolio consisted of $1.27 billion in face value of policy benefits and paid consumers $357 million for their life insurance.

For more information about GWG Holdings, Inc. email or visit

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about our estimates regarding future revenue and financial performance. We may not actually achieve the expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the expectations disclosed in the forward-looking statements we make. More information about potential factors that could affect our business and financial results is contained in our filings with the Securities and Exchange Commission. Additional information will also be set forth in our future quarterly reports on Form 10-Q, annual reports on Form 10-K and other filings that we make with the Securities and Exchange Commission. We do not intend, and undertake no duty, to release publicly any updates or revisions to any forward-looking statements contained herein.

Media contacts: 
Dan Callahan 
GWG Holdings, Inc. 
(612) 746-1935 

Matt Ehlers 
G&S Business Communications 
(919) 870-5718, x3221
Thursday, January 26th, 2017 Uncategorized Comments Off on $GWGH #BrianChen to Lead Development of #Epigenetic #MortalityPrediction Technology

$MEOH Notice of #Cash #Dividend

VANCOUVER, BRITISH COLUMBIA–(Jan. 26, 2017) – Methanex Corporation (TSX:MX)(NASDAQ:MEOH) announced today that its Board of Directors has declared a quarterly dividend of US$0.275 per share that will be payable on March 31, 2017 to holders of common shares of record on March 17, 2017.

Methanex is a Vancouver-based, publicly traded company and is the world’s largest producer and supplier of methanol to major international markets. Methanex shares are listed for trading on the Toronto Stock Exchange in Canada under the trading symbol “MX” and on the NASDAQ Global Market in the United States under the trading symbol “MEOH”. Methanex can be visited online at

Sandra Daycock
Director, Investor Relations
Methanex Corporation
604-661-2600 or Toll Free: 1 800 661 8851

Thursday, January 26th, 2017 Uncategorized Comments Off on $MEOH Notice of #Cash #Dividend